HDT Bio Corp v. Emcure Pharmaceuticals Ltd

District Court, W.D. Washington·Decided December 5, 2023·No. 2:22-cv-00334·Unknown

Opinion

1 2

3 4 5 6 7 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON 8 AT SEATTLE

9 10 HDT BIO CORP., CASE NO. C22-0334JLR 11 Plaintiff, ORDER v. 12 EMCURE PHARMACEUTICALS, 13 LTD., 14 Defendant. 15 I. INTRODUCTION 16 Before the court are four motions to seal, two filed by Plaintiff HDT Bio Corp. 17 (“HDT”) (10/16/23 Mot. (Dkt. #143); 11/10/23 Mot. (Dkt. # 185)), and two filed by 18 Defendant Emcure Pharmaceuticals, Ltd. (“Emcure”) (10/25/23 Mot. (Dkt. # 156); 19 11/6/23 Mot. (Dkt. # 174)). HDT responded to Emcure’s motions (10/25/23 Mot. Resp. 20 (Dkt. # 184); 11/6/23 Mot. Resp. (Dkt. # 192)), and Emcure responded to HDT’s motions 21 (10/16/23 Mot. Resp. (Dkt. # 181); 11/10/23 Mot. Resp. (Dkt. # 194)). Except for HDT’s 22 1 November 10, 2023 motion, the parties filed reply briefs in support of their motions. 2 (10/16/23 Mot. Reply (Dkt. # 190); 10/25/23 Mot. Reply (Dkt. # 191); 11/6/23 Mot.

3 Reply (Dkt. # 193).) The motions concern briefs and other documents related to HDT’s 4 motion to compel (MTC (Dkt. ## 146 (sealed), 144 (redacted)) and Emcure’s motion to 5 dismiss (MTD (Dkt. # 136)). The court has considered the parties’ submissions, the 6 relevant portions of the record, and the governing law. Being fully advised,1 the court 7 GRANTS in part and DENIES in part HDT’s October 16, 2023 motion and Emcure’s 8 October 25, 2023 motion and DENIES Emcure’s November 6, 2023 motion and HDT’s

9 November 10, 2023 motion. 10 II. ANALYSIS 11 A. Legal Standard 12 “There is a strong presumption of public access to the court’s files.” Local Rules 13 W.D. Wash. LCR 5(g); see also Foltz v. State Farm Mut. Auto. Ins. Co., 331 F.3d 1122,

14 1135 (9th Cir. 2003) (“In this circuit, we start with a strong presumption in favor of 15 access to court records.”). The public’s “right of access, however, is not absolute and can 16 be overridden given sufficiently compelling reasons for doing so.” Foltz, 331 F.3d at 17 1135; see also Nixon v. Warner Commc’ns, Inc., 435 U.S. 589, 598 (1978) (“[T]he right 18 to inspect and copy judicial records is not absolute.”). To overcome the presumption of

19 public access, a party must file a motion that includes “[a] specific statement of the 20 applicable legal standard and the reasons for keeping a document under seal, including an 21

1 Neither party requests oral argument, and the court concludes that oral argument would 22 not be helpful to its disposition of these motions. See Local Rules W.D. Wash. LCR 7(b)(4). 1 explanation of” (i) “the legitimate private or public interests that warrant the relief 2 sought”; (ii) “the injury that will result if the relief sought is not granted”; and (iii) “why

3 a less restrictive alternative to the relief sought is not sufficient.” Local Rules W.D. 4 Wash. LCR 5(g)(3)(B)(i)-(iii). 5 Two standards govern sealing motions in the Ninth Circuit. Ordinarily, “a party 6 must show ‘compelling reasons’ to keep a document under seal.” Ctr. for Auto Safety v. 7 Chrysler Grp., LLC, 809 F.3d 1092, 1095 (9th Cir. 2016) (quoting Kamakana v. City & 8 Cnty. of Honolulu, 447 F.3d 1172, 1178 (9th Cir. 2006)). The Ninth Circuit has “carved

9 out an exception,” however, “for sealed materials attached to a discovery motion 10 unrelated to the merits of a case.” Id. at 1097 (quoting Foltz, 331 F.3d at 1135). When 11 such nondispositive motions are “only tangentially related[] to the merits of a case,” “the 12 good cause standard from Rule 26(c)” applies. See id. at 1097, 1099; see also Seattle 13 Times Co. v. Rhinehart, 467 U.S. 20, 33 (1984) (“Much of the information that surfaces

14 during pretrial discovery may be unrelated, or only tangentially related, to the underlying 15 cause of action.”). 16 Although requests to seal documents associated with motions to compel are 17 typically reviewed under the good cause standard, see, e.g., Labbe’ v. Dometic Corp., No. 18 2:20-cv-01975-DAD-DMC, 2023 WL 6519306, at *2 (E.D. Cal. Oct. 4, 2023) (compiling

19 cases), the court applies the “compelling reasons” standard when evaluating the instant 20 motions to seal because HDT’s motion to compel and Emcure’s motion to dismiss are 21 intertwined. (See 12/4/23 Order (Dkt. # 195) (sealed) at 3.) HDT’s motion to compel 22 concerned two emails that it used in its response to Emcure’s motion to dismiss. (See 1 MTD Resp. (Dkt. ## 152 (sealed), 148 (redacted)) at 21.) HDT’s motion to compel is 2 therefore closely related to the merits of the case, and the compelling reasons standard

3 must be satisfied. See Ctr. for Auto Safety, 809 F.3d at 1097. 4 To satisfy the compelling reasons standard, the requesting party must support its 5 argument with “specific factual findings” that demonstrate the reasons for sealing 6 “outweigh the general history of access and the public policies favoring disclosure.” 7 Kamakana, 447 F.3d at 1178-79 (quoting Foltz, 331 F.3d at 1135). “Compelling reasons 8 sufficient to outweigh the public’s interest in disclosure exist when court records might

9 become a vehicle for improper purposes, such as the use of records to gratify private 10 spite, promote public scandal, circulate libelous statements, or release trade secrets.” 11 Demaree v. Pederson, 887 F.3d 870, 884 (9th Cir. 2018) (internal brackets and quotation 12 marks omitted) (quoting Kamakana, 447 F.3d at 1179). The need to keep materials 13 protected by the attorney-client privilege and the work product doctrine confidential may

14 also constitute a compelling reason to justify keeping documents under seal. See 15 Copeland v. Hewlett-Packard Co., 716 F. App’x 603, 609 (9th Cir. 2017). 16 The court addresses the parties’ motions below. 17 B. 10/16/23 Motion to Seal (Dkt. # 143) 18 HDT’s first motion to seal concerns the following documents: (1) portions of and

19 certain exhibits attached to the October 16, 2023 declaration of Dana Berkowitz (Dkt. 20 # 153); (2) portions of the October 16, 2023 declaration of Amit Khandhar (Dkt. # 155); 21 and (3) certain documents designated as Emcure/Gennova confidential. (10/16/23 Mot. 22 at 2-4.) The court considers each in turn. 1 a. Berkowitz Declaration (Dkt. # 153) 2 With exhibits, HDT’s Berkowitz Declaration (Dkt. # 153) is 1,386 pages long.

3 The court addresses HDT’s arguments first and then Emcure’s. 4 HDT does not identify any particular paragraphs or lines it seeks to keep under 5 seal. Instead, HDT broadly seeks to keep confidential “information about suppliers, 6 ingredients, proportions of ingredients, and/or the combination thereof.” (10/16/23 Mot. 7 at 5.) HDT’s statement is far too broad and imprecise to overcome the compelling 8 reasons standard. The court does not even know where to begin, and many pages of the

9 publicly filed version of the declaration (Dkt. # 149) are entirely redacted, making a 10 side-by-side comparison even more impractical than it otherwise would be. Moreover, as 11 the court noted in its previous order, mere ingredients and suppliers listed in HDT’s 12 amended complaint are not trade secrets. (12/4/23 Order at 15-16.) HDT may redact 13 information concerning confidential discussions or agreements with suppliers as well as

14 formulas, recipes, and pricing information that are not publicly available. HDT may not 15 redact supplier names or the materials they sell if that information is in the public 16 domain, such as from the supplier’s website.

Free access — add to your briefcase to read the full text and ask questions with AI

HDT Bio Corp v. Emcure Pharmaceuticals Ltd, (W.D. Wash. 2023).

HDT Bio Corp v. Emcure Pharmaceuticals Ltd (HDT Bio Corp v. Emcure Pharmaceuticals Ltd) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related